Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.55 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | GBA1 | P04062 | 3/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549774 | 0.94 | CYP19A1 (0.62) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL22701235 | 0.92 | CYP19A1 (0.65) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL25836828 | 0.92 | CYP19A1 (0.65) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL22794232 | 0.92 | CYP19A1 (0.65) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL25837226 | 0.92 | CYP19A1 (0.65) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL3546675 | 0.92 | CYP19A1 (0.65) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL14982736 | 0.92 | CYP19A1 (0.50) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL1753748 | 0.88 | CYP19A1 (0.61) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL3560938 | 0.86 | L3MBTL1 (0.55) | L3MBTL1CYP19A1GGPS1HRH4HRH3 | |
| SCHEMBL5020804 | 0.86 | HRH4 (0.58) | L3MBTL1CYP19A1GGPS1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240367146-A1 | HUMIDITY CONTROL AGENT AND DEVICE | DAIKIN INDUSTRIES, LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| CN-118510592-A | Humidity control material and device | 大金工业株式会社 | 2024-08-16 | — | — | CN | disclosed |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| WO-2023140252-A1 | MATERIAL AND DEVICE FOR CONTROLLING HUMIDITY | ダイキン工業株式会社 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023140252-A1 | MATERIAL AND DEVICE FOR CONTROLLING HUMIDITY | ダイキン工業株式会社 | 2023-07-27 | — | — | WO | disclosed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-2999707-B1 | TYLOSIN DERIVATIVES AND METHOD FOR PREPARATION THEREOF | BAYER ANIMAL HEALTH GMBH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2782922-B1 | ANTIBACTERIAL TYLOSIN DERIVATIVES AND METHODS FOR THEIR PREPARATION | BAYER IP GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | NASH HUW M | 2011-10-13 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | L3MBTL1 1750/4885CYP19A1 2366/4885GGPS1 1017/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | L3MBTL1 1325/4885CYP19A1 1866/4885GGPS1 2366/4885 |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | L3MBTL1 709/4885CYP19A1 1614/4885GGPS1 1373/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | L3MBTL1 225/4885CYP19A1 2328/4885GGPS1 2545/4885 |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | L3MBTL1 579/4885CYP19A1 4859/4885GGPS1 3192/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | L3MBTL1 1351/4885CYP19A1 3811/4885GGPS1 2395/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | L3MBTL1 709/4885CYP19A1 1614/4885GGPS1 1373/4885 |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | SLC29A2, SLC29A1, SLC22A3 | L3MBTL1 2413/4885CYP19A1 4772/4885GGPS1 3084/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | L3MBTL1 1368/4885CYP19A1 2899/4885GGPS1 1228/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | L3MBTL1 1713/4885CYP19A1 3250/4885GGPS1 1548/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | L3MBTL1 1005/4885CYP19A1 2887/4885GGPS1 1248/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | L3MBTL1 1351/4885CYP19A1 3811/4885GGPS1 2395/4885 |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | VIP, FLT3, HAVCR2 | L3MBTL1 333/4885CYP19A1 3048/4885GGPS1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.